<DOC>
	<DOCNO>NCT01226485</DOCNO>
	<brief_summary>The purpose study find recommended dose level schedule dose RXDX-109 ( formerly LY2940680 ) safely take patient advanced cancer . The study also explore change cancer marker level skin , hair follicle , buccal cell , tumor cell . Finally , study help document antitumor activity drug may .</brief_summary>
	<brief_title>A Study Advanced Cancer</brief_title>
	<detailed_description>Participants may include previously receive treatment another hedgehog smoothen ( Hh/Smo ) inhibitor ( exclude RXDX-109 ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer advance and/or metastatic . The patient must , judgment investigator , appropriate candidate experimental therapy . Have presence measurable nonmeasurable disease Have adequate organ function , include : Hematologic : Absolute neutrophil count ( ANC ) great equal 1.5 x 109/L , platelet great equal 100 x 109/L , hemoglobin great equal 9 g/dL . Patients may receive erythrocyte transfusion achieve hemoglobin level discretion investigator . Initial treatment must begin 5 day erythrocyte transfusion . Hepatic : Bilirubin le equal 1.5 time upper limit normal ( ULN ) , ALT , aspartate transferase ( AST ) less equal 2.0 time ULN . If liver tumor involvement AST ALT equal less equal 5 time ULN acceptable . Renal : Serum creatinine less equal 1.5 time ULN . Have performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous treatment cancer recover acute effect therapy ( example , least 42 day mitomycinC nitrosoureas , 28 day chemotherapy biologics . At discretion investigator , hormone refractory prostate cancer patient stable gonadotropinreleasing hormone ( GnRH ) agonist therapy breast cancer patient stable antiestrogen therapy ( example , aromatase inhibitor ) may continue treatment Have receive treatment within 21 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication . Have serious preexist medical condition Have symptomatic central nervous system ( CNS ) malignancy ( exception medulloblastoma ) metastasis ( screen require ) . Patients treat CNS metastasis eligible study currently receive corticosteroid and/or anticonvulsant , disease asymptomatic radiographically stable least 60 day . Have know current hematologic malignancy acute chronic leukemia Have know active fungal , bacterial , and/or know viral infection include human immunodeficiency ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) Have second primary malignancy judgment investigator sponsor may affect interpretation result Have QTc interval &gt; 500 msec screen electrocardiogram Patients previously receive treatment LY2940680</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Terminal</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>End Stage</keyword>
	<keyword>Metastatic</keyword>
</DOC>